Wellnex Health Ltd (LON: WNX) improved gross margin from 22.8% to 31.3% in the first half. Breakeven was achieved in the second quarter. The core Pain Away product generated revenues of A$3.3m in the second quarter. The share price gained 13.3% to 8.5p.
Rome Resources (LON: RMR) has two drill rigs operating at the Bisie North copper project in the Democratic Republic of Congo. The initial drill hole has encountered significant tin mineralisation. The share price increased 9.09% to 0.9p.
Shuka Minerals (LON: SKA) has completed the acquisition of Leopard Exploration and Mining and the Kabwe zinc mine following receipt of expected funds There are 5.723Mt of resources at Kabwe (including 700,000 tonnes of zinc and 100,000 tonnes of lead), with a value in excess of $2bn. The NPV10 is $561m. The share price recovered 8.97% to 4.25p.
Polar Capital (LON: PLR) increased assets under management by 6% to £28.3m in the quarter to December 2025. The increase was due to performance. This has helped performance fee estimates to rise to £16m. Full year pre-tax profit is expected to decline from £54.7m to £51.6m. The share price improved 5.93% to 625p.
Europa Oil and Gas (LON: EOG) has gained a two-year extension for the PEDL343 licence with the first phase expiring in March 2028 and the second phase in July 2030. During the first phase 3D seismic will be acquired and an appraisal well will be drilled. The share price rose 4.11% to 1.9p.
Toys and games supplier Character Group (LON: CCT) says like-for-like sales in the fourth months to December 2025 were 11% lower, but sales should improve in the second half. Full year revenues are likely to be flat, but pre-tax profit could more than double. The £2.96m share buyback is completed. The share price is 2.11% higher at 242p.
FALLERS
GCM Resources (LON: GCM) is raising £1m at 6p/share. This will fund further progress towards the development of the Phulbari coal and power project in Bangladesh. There is a General Election in February and there are indications that this could lead to a focus on developing local natural resources. The share price fell 21.9% to 6.25p.
Cancer diagnostics developer CelLBxHealth (LON: CLBX) expects 2025 revenues to be £1.4m, which is lower than the forecast of £1.6m due to deferral of contracts. After the recent fundraising, year-end cash was £7.3m. The 2026 forecast is maintained with revenues of £3.6m and a £5.7m loss after annualised cost savings of £5.9m. The share price slipped 5% to 0.95p.